LOGIN  |  REGISTER
Terns Pharmaceuticals
Assertio

Rani Therapeutics to Participate in September Investor Conferences

September 03, 2024 | Last Trade: US$2.08 0.04 1.96

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include:

H.C. Wainwright 26th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York, NY
Date: Tuesday, September 10, 2024 at 4:30 pm E.T.
Format: Company Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

2024 Cantor Global Healthcare Conference
Location: InterContinental Barclay Hotel, New York, NY
Date: Wednesday, September 18, 2024 at 11:30am E.T.
Format: Fireside Chat and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit www.ranitherapeutics.com

Investor Contact:

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB